Skip to main content
Glama

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the readOnly/idempotent annotations, the description discloses important behaviors: multi-endpoint cascading lookups, graceful degradation when GLEIF/OpenFIGI are down, explicit `unresolved` reporting, and the `figi_candidates` behavior when a name matches multiple instruments. It also explains edge cases like non-equity instruments and ISIN-to-LEI resolution, giving the agent a realistic model of the tool's behavior.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long, but the length is justified by the tool's multi-type, multi-source complexity. It is front-loaded with use cases, organized by entity type, and the critical caveats are placed inline where they are relevant. A slightly tighter edit could reduce repetition, but the structure earns its length.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with no output schema and complex multi-source resolution behavior, the description is remarkably complete: it covers the identifier sets, the source labels, the unresolved behavior, multi-match handling, fallback degradation, and the mapping from an ISIN to a legal entity. An agent has enough to invoke it correctly and anticipate the shape of its results.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Although the schema already covers both parameters at 100%, the description adds substantial meaning: accepted input forms for company (ticker, CIK, ISIN, name) and drug (brand or generic), the exact formatting warning for bonds, and a concrete instruction to pass only the entity name, not the full noun phrase. This goes well beyond the schema's generic descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete trigger phrases and defines the core action: resolving a user-spoken name to the canonical identifiers other tools require. It names the supported entity types (company, drug) and the identifier families returned, making the tool's role unmistakable and distinct from siblings like entity_profile or compare_entities.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives explicit usage direction: 'Use FIRST whenever you have a name but need an ID,' and enumerates many example queries that signal the right moment to call it. It does not explicitly state when NOT to use it or compare it to sibling tools, but the positive guidance is strong and clear.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation2/5

Many tools have overlapping purposes, especially in the prediction market domain (e.g., bet_research, polymarket_edges, polymarket_arbitrage, polymarket_fill_risk) and data querying (ask_pipeworx, ask_pipeworx_grounded, deep_research). This overlap creates confusion for an agent selecting the right tool.

Naming Consistency2/5

Naming is inconsistent: most tools use snake_case but some start with a verb (ask_, bet_, compare_) while others start with a noun (entity_profile, pipeworx_feedback, polymarket_*). There is no uniform pattern, making it harder to predict tool names.

Tool Count2/5

With 32 tools, the server is overstuffed for a single focus. It bundles checksums, AI visibility, data queries, prediction market analysis, subscriptions, memory, and more, which would be better split into separate, more focused servers.

Completeness2/5

Despite the large tool count, the server lacks completeness in key areas: no tool to place prediction market trades, no direct SEC filing detail extraction (only through generic queries), and only two checksum tools despite the server name 'Crc'. The surface feels scattershot rather than comprehensive.